Form 4: Vigil Neuroscience's Chief Medical Officer Receives Stock Option Award

Petra Kaufmann, Chief Medical Officer of Vigil Neuroscience, Inc., was granted a stock option award for 144,000 shares on March 3, 2025.

Summary

• On March 3, 2025, Petra Kaufmann, the Chief Medical Officer of Vigil Neuroscience, Inc. (VIGL), received a stock option award.
• The award grants her the right to buy 144,000 shares of common stock at an exercise price of $2.19 per share.
• The options vest in 48 equal monthly installments, starting on April 3, 2025, and expire on March 3, 2035.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. It reflects a standard executive compensation practice, indicating confidence in the company's future.

Positives

• The stock option award aligns the Chief Medical Officer's interests with those of the shareholders.
• The vesting schedule incentivizes continued service and contribution to the company's success.

Industry Context

Stock options are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align their interests with those of shareholders. The size and terms of the option grant are typical for an executive at this level.

Comparison to Industry Standards

• Stock option grants for Chief Medical Officers in biotech companies of similar size to Vigil Neuroscience typically range from 0.1% to 0.5% of outstanding shares.
• Vesting schedules are also standard, with monthly or quarterly vesting over a 3-4 year period being common.
• Comparable companies like Annexon Biosciences (ANNX) and ALX Oncology (ALXO) have similar equity compensation structures for their executive teams.

Stakeholder Impact

• Shareholders may view the stock option award as a positive sign, aligning management's interests with the company's long-term success.
• Employees may see this as a positive sign of the company's commitment to its leadership team.

Key Dates